Niclosamide Suppresses Cancer Cell Growth By Inducing Wnt Co-Receptor LRP6 Degradation and Inhibiting the Wnt/Î²-Catenin Pathway
MetadataShow full item record
AbstractThe Wnt/b-catenin signaling pathway is important for tumor initiation and progression. The low density lipoprotein receptor-related protein-6 (LRP6) is an essential Wnt co-receptor for Wnt/b-catenin signaling and represents a promising anticancer target. Recently, the antihelminthic drug, niclosamide was found to inhibit Wnt/b-catenin signaling, although the mechanism was not well defined. We found that niclosamide was able to suppress LRP6 expression and phosphorylation, block Wnt3A-induced b-catenin accumulation, and inhibit Wnt/b-catenin signaling in HEK293 cells. Furthermore, the inhibitory effects of niclosamide on LRP6 expression/phosphorylation and Wnt/b-catenin signaling were conformed in human prostate PC-3 and DU145 and breast MDA-MB-231 and T-47D cancer cells. Moreover, we showed that the mechanism by which niclosamide suppressed LRP6 resulted from increased degradation as evident by a shorter half-life. Finally, we demonstrated that niclosamide was able to induce cancer cell apoptosis, and displayed excellent anticancer activity with IC50 values less than 1 mM for prostate PC-3 and DU145 and breast MDA-MB-231 and T-47D cancer cells. The IC50 values are comparable to those shown to suppress the activities of Wnt/b-catenin signaling in prostate and breast cancer cells. Our data indicate that niclosamide is a unique small molecule Wnt/b-catenin signaling inhibitor targeting the Wnt co-receptor LRP6 on the cell surface, and that niclosamide has a potential to be developed a novel chemopreventive or therapeutic agent for human prostate and breast cancer.
CitationPLoS One. 2011 Dec 16; 6(12):e29290
- Rottlerin induces Wnt co-receptor LRP6 degradation and suppresses both Wnt/β-catenin and mTORC1 signaling in prostate and breast cancer cells.
- Authors: Lu W, Lin C, Li Y
- Issue date: 2014 Jun
- Silibinin inhibits Wnt/β-catenin signaling by suppressing Wnt co-receptor LRP6 expression in human prostate and breast cancer cells.
- Authors: Lu W, Lin C, King TD, Chen H, Reynolds RC, Li Y
- Issue date: 2012 Dec
- Salinomycin suppresses LRP6 expression and inhibits both Wnt/β-catenin and mTORC1 signaling in breast and prostate cancer cells.
- Authors: Lu W, Li Y
- Issue date: 2014 Oct
- Niclosamide sensitizes triple-negative breast cancer cells to ionizing radiation in association with the inhibition of Wnt/β-catenin signaling.
- Authors: Yin L, Gao Y, Zhang X, Wang J, Ding D, Zhang Y, Zhang J, Chen H
- Issue date: 2016 Jul 5
- Gigantol inhibits Wnt/β-catenin signaling and exhibits anticancer activity in breast cancer cells.
- Authors: Yu S, Wang Z, Su Z, Song J, Zhou L, Sun Q, Liu S, Li S, Li Y, Wang M, Zhang GQ, Zhang X, Liu ZJ, Lu D
- Issue date: 2018 Feb 14
Showing items related by title, author, creator and subject.
Hydroxyurea induces fetal hemoglobin expression by activating cAMP signaling pathways in a cAMP- and cGMP-dependent mannerIkuta, Tohru; Gutsaeva, Diana R.; Parkerson, James B.; Yerigenahally, Shobha D; Head, C. Alvin; Department of Anesthesiology and Perioperative Medicine (American Society of Hematology, 2010-12)Here we show that hydroxyurea (HU) induces fetal hemoglobin (HbF) expression by activating the cAMP pathway through two independent mechanisms. Although HU increased both cAMP and cGMP levels in CD34+-derived erythroblasts, only the cAMP pathway was found to be activated. However, HU-induced HbF expression was affected by the activities of both adenylate cyclase (AC) and soluble guanylate cyclase (sGC). HU decreased the expression of cGMP-inhibitable phosphodiesterase (PDE) 3B in a sGC-dependent manner, resulting in activation of the cAMP pathway. Second, HU induced the expression of cyclooxygenase-1 (COX-1) and increased the production of prostaglandin E2 (PGE2), which resulted in activation of the cAMP signaling pathway through AC. HU therapy elevated plasma PGE2 levels in sickle cell patients. These results demonstrate that HU induces HbF expression by activating the cAMP pathway via dual signaling mechanisms.
Does the JNK/Jun Signaling Node Regulate Autophagy in Breast Cancer Cells?Joseph, Carol; Department of Cellular Biology and Anatomy; Schoenlein, Patricia V.; Department of Cellular Biology and Anatomy; Augusta University (2018-02-12)A common treatment for estrogen receptor positivebreast cancers is the use of selective estrogen receptor modulators such as Tamoxifen.1Unfortunately, 30-40% of patients experience relapse due tothe development ofantiestrogen resistance. Autophagy, a process that is typically seen in cells that are exposed to a variety of stresses, is critical to development of antiestrogen resistanceand may play a key role in metastatic progression.2,3 To further combat antiestrogen resistance, a potential target for breast cancers is JNK (c-Jun N-terminal kinase), a member of the mitogen-activated protein kinase (MAPK) family. The mechanismsby which JNK inhibition affects breast cancer cell growthare not fully characterized.Our hypothesis is that JNK is a key regulator of autophagy and the emergence of autophagy-dependent antiestrogen resistant breast cancer. Our aims are todetermine the effect of JNK inhibition on autophagy, cell number, and cell viability under conditions of antiestrogen treatment.By utilizingMCF-7breast cancercells andthe irreversible JNK-IN-8 inhibitor our current data provides strong evidence that JNK inhibition blocks autophagy. Data supporting a role for JNK in the regulation of antiestrogen-mediated autophagy have the potential to identify JNK as a molecular target for the improved treatment of breast cancer.
p65fl/fl/LysMCre Transgenic Mouse Model Shows Altered Nf-Kb Signaling In MacrophagesHoward, Shelby; Talkad, Aditi; Oza, Eesha; Department of Biological Sciences (2016-03)We have produced and begun characterizing a transgenic mouse model, p65fl/fl/LysMCre, that lacks canonical nuclear factor-kappaB (NF-kB) signaling (p65) in cells of the myeloid lineage, which includes macrophages. NF-kB pathway activity is very important in normal immune function, synaptic plasticity, and memory, and aberrant NF-kB activity is associated with autoimmune disease, and importantly, cancer. Macrophages can be present in very large numbers in a variety of cancers, and can lead to tumor progression through promotion of tumor inflammation, angiogenesis, invasion, and metastasis. This animal model will allow our group to pursue experiments involved in better understanding how stromal macrophages communicate with cancer cells through the NF-kB pathway, and how loss of canonical NF-kB signaling in cells of the myeloid lineage might weaken the tumor and make it more susceptible to standard treatments. Characterization of the model thus far reveals that p65 protein is indeed absent in macrophages derived from bone marrow monocytes, and that NF-kB signaling is altered when stimulated with lipopolysaccharide. We have just begun co-culture experiments with p65 deleted macrophages and glioma cells, and anticipate altered communication when compared to culture with control macrophages. Funding Source: Cancer Center Collaboration Grant